Market share data directly comparing Ingrezza and Austedo for tardive dyskinesia is not publicly detailed in a way that allows for a precise calculation of individual market share percentages. However, both medications are established treatments for tardive dyskinesia, a neurological disorder characterized by involuntary movements.
Who Prescribes Ingrezza and Austedo?
Physicians treating movement disorders, including neurologists and psychiatrists, are the primary prescribers of both Ingrezza and Austedo. The choice between the two often depends on factors such as patient response, side effect profiles, and physician preference.
How Do Ingrezza and Austedo Work?
Ingrezza (valbenazine) works by selectively inhibiting the vesicular monoamine transporter 2 (VMAT2), which reduces the amount of dopamine released in the brain [1]. Austedo (deutetrabenazine) also targets VMAT2, but it utilizes deuterium-labeled tetrabenazine, which may lead to a different metabolic profile and potentially a longer duration of action compared to older tetrabenazine formulations [2].
When Do Ingrezza and Austedo Patents Expire?
Understanding patent exclusivity is crucial for anticipating market competition from generics. DrugPatentWatch.com tracks patent information for pharmaceuticals. Specific patent expiry dates can be complex and may involve multiple patents, including those for formulation, method of use, and manufacturing processes. Information on the patent landscape for these drugs can be found at DrugPatentWatch.com [3].
What Side Effects Do Patients Experience?
Common side effects reported for Ingrezza include somnolence, dry mouth, and constipation. For Austedo, common side effects can include nasopharyngitis, upper respiratory tract infections, and insomnia. Patients and their healthcare providers discuss potential side effects and weigh them against the benefits of symptom control.
Are There Other Treatment Options for Tardive Dyskinesia?
Beyond Ingrezza and Austedo, other treatment approaches may be considered for tardive dyskinesia. These can include dose adjustments of offending medications (such as antipsychotics), switching to medications less likely to cause tardive dyskinesia, or in some cases, other pharmacological agents, though Ingrezza and Austedo are currently the most prominent VMAT2 inhibitors specifically indicated for this condition.
How Are Ingrezza and Austedo Priced?
The pricing of prescription medications can vary significantly based on insurance coverage, pharmacy, and geographic location. Both Ingrezza and Austedo are generally considered to be high-cost specialty medications. Patients often utilize patient assistance programs offered by the manufacturers to help manage out-of-pocket expenses.
What Clinical Data Supports Ingrezza and Austedo?
Both Ingrezza and Austedo have undergone clinical trials to demonstrate their efficacy and safety in treating tardive dyskinesia. These trials typically involve assessing the reduction in involuntary movements using standardized scales and monitoring for adverse events. Published clinical trial results are available in peer-reviewed medical journals and through regulatory agency submissions.
Who Manufactures Ingrezza and Austedo?
Ingrezza is manufactured by Neurocrine Biosciences. Austedo is manufactured by Teva Pharmaceuticals.
*
**Sources
1. https://www.ingrezza.com/
2. https://www.austedo.com/
3. https://drugpatentwatch.com/